Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756543 | 1.00 | GPR119 (0.52) | GPR119USP30KDM4EPKMTP53 | |
| SCHEMBL20469562 | 0.78 | TP53 (0.46) | GPR119KDM4EPKMTP53THRB | |
| SCHEMBL5575428 | 0.76 | MEN1 (0.49) | GPR119USP30KDM4EPKMTP53 | |
| SCHEMBL5575439 | 0.76 | MEN1 (0.49) | GPR119USP30KDM4EPKMTP53 | |
| SCHEMBL3604813 | 0.73 | USP30 (0.59) | GPR119USP30KDM4EPKMJAK2 | |
| SCHEMBL4609959 | 0.73 | GPR119 (0.46) | GPR119USP30KDM4EPKMTP53 | |
| SCHEMBL4609951 | 0.73 | GPR119 (0.46) | GPR119USP30KDM4EPKMTP53 | |
| SCHEMBL4598325 | 0.72 | CCR5 (0.54) | GPR119USP30KDM4ETP53THRB | |
| SCHEMBL4596495 | 0.72 | GPR119 (0.49) | GPR119USP30KDM4EPKMJAK2 | |
| SCHEMBL4596490 | 0.72 | GPR119 (0.49) | GPR119USP30KDM4EPKMJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | GPR119 207/4885USP30 4287/4885KDM4E 4532/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | GPR119 207/4885USP30 4287/4885KDM4E 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.